The successful treatment of mpox with brincidofovir in renal transplant recipients—a report of 2 cases

•Mpox in immunosuppressed hosts tends to cause severe disseminated infection.•Literature on mpox treatment in solid organ transplant recipients is limited.•Tecovirimat is the treatment of choice in severe disease.•Brincidofovir might be a reasonable alternative when tecovirimat is unavailable. An mpox outbreak was declared in July 2022 by the world health organization (WHO). It causes a mild self-limiting disease however; in immunosuppressed hosts, it tends to cause severe disseminated infection. Most cases of mpox in sold organ transplant (SOT) recipients reported in the literature were treated with tecovirimat. Here we report two cases of severe disseminated mpox infection in renal transplant recipients that were successfully treated with brincidofovir. Both patients were discharged from the hospital with no immediate significant side effects from brincidofovir reported until the submission of this report.